Equity Overview
Price & Market Data
Price: $12.60
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $20,232,576
Volume: 0
Performance Metrics
1 Week: -2.54%
1 Month: -9.64%
3 Months: 15.00%
6 Months: 5.42%
1 Year: 416.3%
YTD: 11.95%
Company Details
Employees: 1
Sector: Health services
Industry: Medical/Nursing services
Country: United States
Details
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.